Google-backed Isomorphic raises $2.1 billion to scale AI-driven drug discovery

May 12, 2026 11:21 AM EDT

Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026. REUTERS/Denis Balibouse/File Photo

May 12 (Reuters) - Isomorphic Labs, ‌an artificial ​intelligence-driven ​drug discovery company, said on Wednesday it has raised $2.1 billion in its latest funding round led by existing ‌investor Thrive Capital.

The funding round, completed at an undisclosed ⁠valuation, also included other existing investors, Google Ventures and Alphabet, along with ‌new backers MGX, Temasek ‌and CapitalG.

The development comes amid a broader industry push to demonstrate practical applications of AI in the healthcare sector, including ​its ability to accelerate research and development along with shortening drug discovery timelines.

"This capital injection allows us to build out ⁠our drug design engine at scale, driving us forward in our mission to solve ​all diseases," said founder and CEO Demis Hassabis.

Isomorphic was founded in 2021 as a spin-off from Google ​DeepMind, an AI research lab acquired ‌by Alphabet in 2014.

One of DeepMind and Hassabis' most celebrated breakthroughs was AlphaFold, an AI program ⁠that can predict protein structures, which can help scientists design drugs and target diseases more effectively.

"Now that we have shown our approach is ⁠fundamentally sound, our focus is on scaling our technology to its full ​potential," said Hassabis.

The company now expects its first clinical trials by the end of 2026 — a delay from the CEO's earlier target of having ‌AI-designed drugs in trials by the end of 2025.

The London-based company raised $600 million in its first ‌funding round last year, also led by Thrive Capital, a major ⁠backer of AI-focused companies.

The company ‌did not immediately ​respond to a Reuters request for comment on the valuation.

(Reporting by Pritam Biswas in Bengaluru; Editing by ‌Vijay Kishore)



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

General News, Reuters

Related Entities

Temasek Holdings